MLYS Mineralys Therapeutics
- 14.270
- -0.380-2.59%
Mineralys Therapeutics News
Mineralys Therapeutics: Strong Buy on Upcoming ADVANCE Trial Results and Robust Financial Health
Analysts Are Bullish on These Healthcare Stocks: Mineralys Therapeutics, Inc. (MLYS), Anika Therapeutics (ANIK)
Express News | Mineralys Therapeutics Q1 2024 GAAP EPS $(0.70) Misses $(0.67) Estimate
Mineralys Therapeutics | 10-Q: Quarterly report
Express News | Mineralys Therapeutics Inc - Current Cash, Cash Equivalents and Investments Will Be Sufficient to Fund Its Planned Clinical Studies Into 2026
Express News | Mineralys Therapeutics Inc - Ongoing Explore-Ckd Phase 2 Trial Is Anticipated to Deliver Topline Data in Q4 2024 to Q1 2025
Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $338.6M as of March 31 >MLYS
Mineralys Therapeutics Cash, Cash Equivalents and Investments Were $338.6M as of March 31 >MLYS
Express News | Mineralys Therapeutics Q1 EPS USD -0.7
Express News | Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Express News | Mineralys Therapeutics Q1 Net Income USD -31.508 Million
Express News | Mineralys Therapeutics Q1 Operating Expenses USD 35.362 Million
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference
RADNOR, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ:MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD)
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic
Mineralys Therapeutics Board Member Announces Departure
Goldman Starts Mineralys at Buy, Cites Upcoming Drug Data
QuidelOrtho Stock Falls 11% on Savanna PVP4+ Assay Update
Express News | Mineralys Therapeutics Shares Are Trading Higher After Goldman Sachs Initiated Coverage on the Stock With a Buy Rating and Announced a Price Target of $30
Express News | Goldman Sachs Initiates Coverage On Mineralys Therapeutics With Buy Rating, Announces Price Target of $30
Mineralys Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/02/2024 126.93% Goldman Sachs → $30 Initiates Coverage On → Buy 08/08/2023 179.88% Credit Suisse $38 →
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Q4 2023 Earnings Call Transcript
Analysis
Price Target
No Data
